Spearheading Safe, Potent, & Scalable Innate Immune Therapies Spanning NK, iNKT, Gamma Delta, & Macrophages.
Realize Lasting Clinical Response with Next-Generation Engineering to Provide Off-the-Shelf Delivery for More Patients, Globally.

Driving Clinical Results with Allogeneic & Solid Tumor Innate Therapies

Dedicated to driving cost-effective, efficacious, safe, durable, scalable, and globally accessible allogeneic, cell-based, and engager therapies, the 8th Innate Killer Summit returns to cement your end-to-end education in innate immune therapeutics. Your industry-defining Innate Killer Summit brings crucial insights for everyone on your team, spanning preclinical development, clinical translation, CMC, process development, and clinical scale manufacturing, this is the definitive meeting to drive concept to commercial success of emerging innate immune therapies.

Download your copy of the Full Event Guide here.

Join over 250 experts from 120+ pioneering companies to drive novel gene engineering technologies, gain regulatory know-how, optimize lymphodepletion and cryopreservation, and contrast cell sources for highly efficacious, scalable off-the-shelf therapies.

Promising brand-new speakers from new companies, interactive discussion, and engaging networking opportunities join the 8th Innate Killer Summit to forge new collaborations and realize the clinical potential of innate immune therapies.

70+ Industry-Leading Speakers Include:

Robert Hollingsworth

Chief Scientific Officer

Shoreline Biosciences

Neil Sheppard

Director & Head of Research Technologies & Innovation T Cell Engineering Laboratory & Cellular Immunotherapies

University of Pennsylvania

Mark Lowdell

CSO & Founder

InMune Bio

Richard Wang

Chief Executive Officer

Neukio Biotherapeutic

Christina Coughlin

Chief Executive Officer

CytoImmune Therapeutics

Sasha Lazetic

Director NK Platform & Binder Development

Nkarta Therapeutics

Jeffrey Miller

Professor - Medicine Division Hematology & Transplantation Oncology

University of Minnesota

Jason Litten

Chief Medical Officer

Chimeric Therapeutics

Evren Alici

Group leader, Cell and Gene Therapy

Karolinska Institutet

Terry Cook

Sr Director Early Clin Dev

Century Therapeutics

Peter Flynn

Co-Founder, COO

Artiva Biotherapeutics, Inc

Arndt Schottelius

Chief Scientific Officer


A Snapshot of this Year's Partners:

Lead Partner:

Industry Partner: